Navigation Links
Bone-Strengthening Drug Guards Against Spread of Breast Cancer
Date:4/1/2010

Zoledronic acid protected against chemotherapy-related bone loss, metastasis, study finds

WEDNESDAY, March 31 (HealthDay News) -- The bone-strengthening drug zoledronic acid (Zometa) reduces the spread of breast cancer by preventing chemotherapy-related bone loss, a new study suggests.

Tumor cells released from the primary breast cancer site often travel to the bone marrow and spread from there to other areas of the body. Chemotherapy speeds up bone turnover, which releases bone-derived growth factors that can promote tumor growth in breast cancer patients.

It's been suggested that zoledronic acid -- which reduces bone loss by slowing the activity of cells that destroy bone -- can make bone marrow a less inviting place for cancer cells.

The new phase 2 trial included 120 women undergoing chemotherapy for locally advanced breast cancer. Some of the patients received 4 milligrams of zoledronic acid every three weeks for one year starting with their first dose of chemotherapy, while others received no zoledronic acid.

Bone marrow samples were taken at the start of the study and again after three months and one year of treatment. At the start of the study, 45.7 percent of patients had detectable tumor cells in their bone marrow. After three months of treatment, women who received zoledronic acid and chemotherapy had fewer detectable tumor cells than those who received chemotherapy alone, according to Rebecca Aft, of the Washington University School of Medicine in St. Louis, and colleagues.

Among women who had no tumor cells in their bone marrow at the start of the study, 87 percent of those in the zoledronic acid group were free of tumor cells at three months, compared with 60 percent of those who received chemotherapy alone. One year after treatment, the rates were 40 percent and 33 percent, respectively, the study authors noted.

The researchers also found that zoledronic acid prevented chemotherapy-related bone loss. Among patients who had low bone mineral density at the start of the study, 44 percent of those who took zoledronic acid had normal bone density after one year and significant decreases in bone-turnover markers at three months and one year.

The study, which appears online March 31 in The Lancet Oncology, was funded by Novartis Pharmaceuticals and Pfizer Inc.

More information

The U.S. National Cancer Institute has more about breast cancer treatments.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, March 31, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. OldHouseWeb.com Educates Homeowners on Lead Poisoning Safeguards During National Poison Prevention Week
2. Vitamin D Plus Calcium Guards Against Fractures
3. Exercise Guards White Blood Cells Against Aging
4. Research confirms that some forms of massage help against low-back pain
5. Study finds surgical masks provided effective protection of health-care workers against H1N1
6. IPhone App is New Tool in the Fight Against Breast Cancer
7. Food Safety Attorney Fred Pritzker Calls for Criminal Sanctions Against Food Poisoners
8. Motherhood a Buffer Against Suicide
9. State Legislators Last Line of Defense Against ObamaCare
10. Poorly understood cell plays role in immunity against the flu
11. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 2017 , ... The city of Los Angeles is a west coast style fashion center as ... Style List, a website that spotlights fashion news from Los Angeles and around the world, ... long. , According to the senior editor of latsl.com , “For a business that ...
(Date:8/15/2017)... ... August 15, 2017 , ... Horizon Goodwill ... McCain said, “We are overwhelmed with gratitude for the very generous donation from ... need assistance to both get a job and keep it. This donation will ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading dental marketing ... 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The Tampa Bay ... has shown three consecutive years of growth. For this year’s award, Progressive Dental ranked ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... announced today the introduction of the innovative new 10x10 bladder pad ( isocomforter.com/product/10x10-sterile-pad/ ... The plush design enhances comfort and enables the patient to enjoy the benefits ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... referral for Snap-on Smile® consultations. Patients interested in orthodontics, dental crowns and ... option. Dr. Nash provides Snap-on Smile treatment at his state-of-the-art practice, Nash Family ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... Israel , Aug. 11, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... on Monday, August 14 and host a conference call ... quarter 2017 operating and financial results and its strategy ... will be hosted by Erez Raphael , Chief ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
(Date:8/7/2017)... 7, 2017  Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...
Breaking Medicine Technology: